Dana Investment Advisors Inc. Has $221,000 Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Dana Investment Advisors Inc. raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 17.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 17,608 shares of the biotechnology company’s stock after purchasing an additional 2,627 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Rocket Pharmaceuticals were worth $221,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Arizona State Retirement System increased its position in Rocket Pharmaceuticals by 8.4% during the 4th quarter. Arizona State Retirement System now owns 19,826 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 1,528 shares during the period. Torray Investment Partners LLC increased its position in Rocket Pharmaceuticals by 66.3% during the 4th quarter. Torray Investment Partners LLC now owns 122,095 shares of the biotechnology company’s stock valued at $1,535,000 after purchasing an additional 48,671 shares during the period. Charles Schwab Investment Management Inc. increased its position in Rocket Pharmaceuticals by 15.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company’s stock valued at $8,247,000 after purchasing an additional 86,276 shares during the period. Bank of New York Mellon Corp increased its position in Rocket Pharmaceuticals by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 194,182 shares of the biotechnology company’s stock valued at $2,441,000 after purchasing an additional 9,949 shares during the period. Finally, Handelsbanken Fonder AB increased its position in Rocket Pharmaceuticals by 26.9% during the 4th quarter. Handelsbanken Fonder AB now owns 23,100 shares of the biotechnology company’s stock valued at $290,000 after purchasing an additional 4,900 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT opened at $8.77 on Monday. The company has a fifty day simple moving average of $10.61 and a 200 day simple moving average of $14.30. Rocket Pharmaceuticals, Inc. has a 12-month low of $8.25 and a 12-month high of $28.73. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a market cap of $935.15 million, a P/E ratio of -3.19 and a beta of 1.03.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06. Sell-side analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Leerink Partners decreased their target price on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Jefferies Financial Group initiated coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $29.00 price objective for the company. The Goldman Sachs Group lowered their price objective on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Scotiabank lifted their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Finally, Canaccord Genuity Group lowered their price objective on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.30.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.